Régis Bordet

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

J. Corvol, J. Kluza, F. Auger, 2014, Antioxidants & redox signaling.

Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.

R. Bordet, D. Devos, C. Laloux, 2012, Pharmacological research.

Study of Circadian Melatonin Secretion Pattern at Different Stages of Parkinson's Disease

A. Destée, J. Guieu, R. Bordet, 2003, Clinical neuropharmacology.

Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease

D. Devos, Luc Defebvre, Régis Bordet, 2010, Fundamental & clinical pharmacology.

Heart rate variability and Parkinson’s disease severity

A. Destée, J. Guieu, R. Bordet, 2003, Journal of Neural Transmission.